acalabrutinib & zanubrutinib for relapsed/refractory mantle cell lymphoma - blood cancers library
Published 1 year ago • 138 plays • Length 4:40Download video MP4
Download video MP3
Similar videos
-
7:19
ibrutinib for relapsed/refractory mantle cell lymphoma - blood cancers video library
-
3:52
glofitamab & pirtobrutinib for relapsed/refractory mantle cell lymphoma -blood cancers video library
-
3:00
the shine study: adding ibrutinib to br - blood cancers video library
-
4:42
the triangle study: ibrutinib maintenance - blood cancers video library
-
5:51
tumor infiltrating lymphocytes and tumor associated macrophages - bladder cancer video library
-
0:47
alpine results: zanubrutinib vs. ibrutinib in cll
-
17:30
gracecast-084_lung-cancer_alk inhibition: science and early clinical experience by dr. ben solomon
-
4:06
grace targeted therapies lung cancer 2021 options after progression on alectinib?
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib
-
2:01
grace targeted therapies lung cancer 2021 - data learned from ensartinib for ros1 in clinical trial?
-
3:00
safety and efficacy of the novel btk inhibitor zanubrutinib in patients with cll/sll
-
6:14
amivantamab and lazertinib in patients with egfr nsclc - 2022 program: targeted therapies forum
-
0:58
alpine: qol in patients with r/r cll treated with zanubrutinib vs ibrutinib
-
5:42
gracecast - lcvl- what are the options after a patient with an alk-positive advanced nsclc develops
-
3:33
grace targeted therapies in lung cancer 2021 - liquid biopsies - tki resistance for alk, ros1 & ret
-
0:54
phase ib/ii trial of 177lu-girentuximab with cabozantinib and nivolumab in clear cell rcc